The study purpose is assessment of the effects of terminalia chebula on hemorrhoid treatment in the patients with hemorrhoids refered to the Modarres hospital. This study is a randomized (based on randomized numbers table) double-blind placebo-controlled trial. Sample size is 40 patients in each group. Study duration is 4 weeks. In this study after taking a complete history, examination and rectosigmoidoscopy, the experimental group will receive one terminalia chebula capsule and the control group will receive one placebo capsule every 6 hours, on an empty stomach for four weeks. If the patients don’t get any response from the treatment (capsules), they can use 30 to 60 cc lactulose syrup to improve constipation and one antihemorrhoids suppository to decrease pain in each day. Inclusion criteria include 18 to 65 year-old women and men who have grade I and II hemorrhoids. Exclusion criteria include every severe disease; presence of cancer in every part of the body; every disease in anorectal except hemorrhoids; pregnant and lactating women; patients with history of using anticoagulant, antiplatelet drugs, steroids drugs, drugs with flavonoids (less than a month ago) and pain killers (less than a week ago). Primary outcomes: pain, hemorrhoids bleeding and constipation are measured respectively based on VAS, number of days and ROM III criteria before and after the intervention, at the end of every week, for four weeks. Size of mass, as primary outcome in hemorrhoids, is measured before the intervention and at the end of the intervention by rectosigmoidoscopy. Secondary outcomes: headache, vertigo, diarrhea, constipation and dry skin are measured based on questionnaire before and after the intervention, at the end of every week, for four weeks.